Abstract 934: A pooled investigation of circulating adiponectin levels and risk of multiple myeloma
Notice bibliographique
Résumé
Abstract Background: Excess body weight throughout adult life has been consistently associated with an increased risk of multiple myeloma (MM). This association may be due in part to reduced expression of adiponectin, as circulating levels of this anti-inflammatory hormone are typically lower in obese individuals compared with those of normal body weight. Studies conducted in vitro and in animal models have found that adiponectin induces myeloma cell apoptosis. Furthermore, in a recent prospective study in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, we observed a lower risk of MM among those with higher pre-diagnosis circulating levels of adiponectin. To follow up on our findings from PLCO and increase our statistical power for analyses stratified by sex, follow-up time, and other factors, we conducted a pooled investigation of circulating adiponectin levels and MM risk using the NCI Cohort Consortium. Methods: Our study included pre-diagnosis peripheral blood samples from 450 MM cases and 898 individually-matched controls from the following 6 cohorts: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; the Cancer Prevention Study II; the Health Professionals Follow-up Study; the Melbourne Collaborative Cohort Study; the Nurses’ Health Study; and the Women's Health Initiative. We performed additional analyses incorporating data from our original investigation in PLCO for a total of 624 MM cases and 1,246 controls. Circulating levels of total adiponectin were measured in duplicate using standard enzyme-linked immunosorbent assay (ELISA) methods. We used conditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for risk of MM in relation to quartiles of cohort- and sex-adjusted adiponectin levels based on the distribution among controls. Results: Higher circulating levels of adiponectin were associated with a reduced risk of MM in the independent replication set (highest quartile vs. lowest: OR 0.68, 95% CI 0.48-0.96; P-trend = 0.02) and in the combined set including PLCO (OR 0.64, 95% CI 0.47-0.85; P-trend = 0.001). This association was also present in analyses restricted to cases diagnosed 6 or more years after blood collection (OR 0.60, 95% CI 0.40-0.90; P-trend = 0.004). The observed associations were similar in magnitude for men and women (ORs of 0.59 and 0.66, respectively), and results were unchanged after adjustment for body mass index. Conclusions: The findings of this pooled investigation provide the strongest epidemiologic evidence to date that adiponectin may protect against development of MM. Further research is needed to characterize the role of this metabolic hormone in progression from the MM precursor monoclonal gammopathy of undetermined significance to clinically manifest disease, and to evaluate the clinical implications of our findings for risk reduction and therapy for MM and associated bone disease. Citation Format: Jonathan N. Hofmann, Brenda M. Birmann, Lauren R. Teras, Ye Wang, Demetrius Albanes, Dalsu Baris, Graham A. Colditz, Anneclaire J. De Roos, Graham G. Giles, Lindsay M. Morton, H. Dean Hosgood, Qing Lan, Ola Landgren, Linda M. Liao, Ruth M. Pfeiffer, Nathaniel Rothman, Stephanie J. Weinstein, Michael N. Pollak, Marian L. Neuhouser, Mark P. Purdue. A pooled investigation of circulating adiponectin levels and risk of multiple myeloma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 934. doi:10.1158/1538-7445.AM2015-934
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,015 | 0,020 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,001 |
| Méta-épidémiologie (sens large) | 0,002 | 0,006 |
| Bibliométrie | 0,003 | 0,005 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,001 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».